eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 68
Review paper

Mast cells as the strength of the inflammatory process

Joanna Pastwińska, Justyna Agier, Jarosław Dastych, Ewa Brzezińska-Błaszczyk

Pol J Pathol 2017; 68 (3): 187-196
Online publish date: 2017/11/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The inflammatory process is a complex host defence mechanism aimed at the elimination of deleterious factors disturbing homeostasis. Inflammation consists of several interdependent stages controlled by a wide range of mediators. Those include acute phase proteins, heat shock proteins, complement components, biogenic amines, cytokines, lipid-derived mediators, reactive oxygen species, nitric oxide, proteolytic enzymes, and kinins. Due to the strategic location in the body, mast cells play a protective role in the inflammatory process, through its initiation, amplification, and resolution. Mast cells degranulate and/or newly produce, and release various mediators classified into three groups: preformed mediators, de novo synthesised lipid mediators, and newly synthesised cytokines. Those mediators have an impact on different processes occurring during inflammation, inter alia, they influence blood vessels leading to dilation, enhanced adhesion molecule expression, and increased permeability. Furthermore, mast cell mediators play a pivotal role in inflammatory cell chemotaxis, degradation of extracellular matrix proteins, impact on stationery cells and resolution of inflammation. The release of mast cell mediators and their actions constitute a highly complex and still not fully understood mechanism, which warrants further studies of the action of mast cells in inflammation. This review will focus on the current knowledge concerning the broad role of mast cells in the inflammatory process.

mast cells, inflammation, mediators, cytokines

Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biol 2011; 6: 274-281.
Ashley NT, Weil ZM, Nelson RJ. Inflammation: mechanisms, costs, and natural variation. Annu Rev Ecol Evol Syst 2012; 43: 385-406.
Kumar R, Clermont G, Vodovotz Y, et al. The dynamics of acute inflammation. J Theor Biol 2004; 230: 145-155.
Sugimoto MA, Sousa LP, Pinho V, et al. Resolution of inflammation: what controls its onset? Front Immunol 2016; 7: 160-177.
Headland SE, Norling LV. The resolution of inflammation: principles and challenges. Semin Immunol 2015; 27: 149-160.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
Muller WA. Getting leukocytes to the site of inflammation. Vet Pathol 2012; 50: 7-22.
Cray C, Zaias J, Altman NH. Acute phase response in animals: a review. Comp Med 2009; 59: 517-526.
Herpers BL, Endeman H, de Jong BAW, et al. Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol 2009; 156: 488-494.
Yenari MA, Liu J, Zheng Z, et al. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann NY Acad Sci 2005; 1053: 74-83.
Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol 2005; 175: 2777-2782.
Oikonomopoulou K, Ricklin D, Ward PA, et al. Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol 2012; 34: 151-165.
MacGlashan D. Histamine: a mediator of inflammation. J Allergy Clin Immunol 2003; 112 (Suppl): S53-S59.
Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 2014; 1843: 2563-2582.
Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol 2008; 79: 1520-1526.
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397-411.
Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice. J Mol Med 2009; 87: 1015-1022.
Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res 2014: 6: 288-295.
Nowak JZ. Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Postepy Hig Med Dosw 2010; 64: 115-132.
Pejler G, Rönnberg E, Waern I, et al. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 2010; 115: 4981-4990.
Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41.
Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011; 12: 233-239.
Golias C, Charalabopoulos A, Stagikas D, et al. The kinin system – bradykinin: biological effects and clinical implications. Multiple role of the kinin system – bradykinin. Hippokratia 2007; 11: 124-128.
da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem 2014; 62: 698-738.
Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol 2016; 6: 620.
Moon TC, St Laurent CD, Morris KE, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3: 111-128.
Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822: 21-33.
Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125 (Suppl 2): S73-S80.
Bandara G, Beaven MA, Olivera A, et al. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur J Immunol 2015; 45: 3034-3044.
Agier J, Brzezińska-Błaszczyk E. Cathelicidins and defensins regulate mast cell antimicrobial activity. Postepy Hig Med Dosw 2016; 70: 618-636.
Brzezińska-Błaszczyk E, Wierzbicki M. Mast cell toll-like receptors (TLRs). Postepy Hig Med Dosw 2010; 64: 11-21.
Kulka M, Metcalfe DD. TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol Immunol 2006; 43: 1579-1586.
Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010; 14: 2592-2603.
Bąbolewska E, Brzezińska-Błaszczyk E. Mast cell inhibitory receptors. Postepy Hig Med Dosw 2012; 66: 739-751.
Amin K. The role of mast cells in allergic inflammation. Respir Med 2012; 106: 9-14.
Dastych J, Wyczółkowska J, Metcalfe DD. Characterization of 5-integrin-dependent mast cell adhesion following FcRI aggregation. Int Arch Allergy Immunol 2001; 125: 152-159.
Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol 2008; 38: 489-499.
Mekori YA, Hershko AY. T cell-mediated modulation of mast cell function: heterotypic adhesion-induced stimulatory or inhibitory effects. Front Immunol 2012; 3: 6.
Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. Cell Mol Life Sci 2011; 68: 965-975.
Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol 2014; 5: 569-586.
Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol 2014; 14: 478-494.
Kempuraj D, Caraffa A, Ronconi G, et al. Are mast cells important in diabetes? Pol J Pathol 2016; 67: 199-206.
Hueber AJ, Asquith DL, Miller AM et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184: 3336-3340.
Palaska I, Gagari E, Theoharides TC. The effects of P. gingivalis and E. coli LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease. J Biol Regul Homeost Agents 2016; 30: 655-664.
Nakayama S, Yokote T, Hiraoka N et al. Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int J Immunopathol Pharmacol 2016; 29: 603-611.
Carinci F, Lessiani G, Spinas E et al. Mast cell and cancer with special emphasis on il-37 an anti-inflammatory and inhibitor of innate immunity: new frontiers. J Biol Regul Homeost Agents 2016; 30: 945-950.
Frenzel L, Hermine O. Mast cells and inflammation. Joint Bone Spine 2013; 80: 141-145.
Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev 2007; 217: 19-37.
Zhang J, Alcaide P, Liu L, et al. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS ONE 2011; 6: e14525.
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad 2012; 88: 53-71.
de Vries VC, Noelle RJ. Mast cell mediators in tolerance. Curr Opin Immunol 2010; 22: 643-648.
Landolina N, Gangwar RS, Levi-Schaffer F. Mast cells’ integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy. In: Advances in Immunology. Alt FW (ed.). Academic Press 2015; 125: 41-85.
Kumara V, Sharma A. Mast cells: Emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol 2010; 48: 14-25.
Apostolakis S, Lip GYH, Shantsila E. Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair? Cardiovasc Res 2010; 85: 649-660.
Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann-Dziurdzińska K, et al. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postep Derm Alergol 2014; 31: 84-91.
Bradding P, Arthur G. Mast cells in asthma – state of the art. Clin Exp Allergy 2015; 46: 194-263.
Kołaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13: 159-175.
Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121.
Sismanopoulosa N, Delivanisa DA, Alysandratos KD, et al. Mast cells in allergic and inflammatory diseases. Curr Pharm Des 2012; 18: 2261-2277.
Frossi B, Gri G, Tripodo C, et al. Exploring a regulatory role for mast cells: ‘MCregs’? Trends Immunol 2010; 31: 97-102.
Tam A, Wadsworth S, Dorscheid D, et al. The airway epithelium: more than just a structural barrier. Ther Adv Respir Dis 2011; 5: 255-273.
Woodman L, Siddiqui S, Cruse G, et al. Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-1. J Immunol 2008; 181: 5001-5007.
Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: introduction and overview. Adv Exp Med Biol 2011; 716: 2-12.
Zhao W, Oskeritzian CA, Pozez AL, et al. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J Immunol 2005; 175: 2635-2642.
Roy A, Ganesh G, Sippola H, et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem 2014; 289: 237-250.
Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432: 512-516.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe